Triacylglycerol-rich lipoprotein margination: A potential surrogate for whole-body lipoprotein lipase activity and effects of eicosapentaenoic and docosahexaenoic acids

American Journal of Clinical Nutrition

Volumn 80, Issue 1, 2004, Pages 45-50

  Park, Yongsoon ^a   Jones, Philip G ^b   Harris, William S ^a,b,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b St Lukes Hospital   (United States)

^c Lipid and Diabetes Research Center   (United States)

Author keywords

Chylomicrons; Docosahexaenoic acid; Eicosapentaenoic acid; Lipoprotein lipase; Margination; N 3 fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; HEPARIN; ICOSAPENTAENOIC ACID; LIPOPROTEIN; LIPOPROTEIN LIPASE; OLIVE OIL; OMEGA 3 FATTY ACID; PLACEBO; SAFFLOWER OIL; TRIACYLGLYCEROL;

ARTICLE; BINDING AFFINITY; CALCULATION; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; ENDOTHELIUM; ENZYME ACTIVITY; HALF LIFE TIME; HUMAN; NORMAL HUMAN; PLASMA VOLUME; SUPPLEMENTATION; ADULT; AGED; BLOOD; BLOOD VOLUME; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIET SUPPLEMENTATION; DIET THERAPY; DOUBLE BLIND PROCEDURE; FEMALE; HYPERLIPIDEMIA; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

CARTHAMUS TINCTORIUS;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD VOLUME; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FASTING; FATTY ACIDS, OMEGA-3; FEMALE; HEPARIN; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; POSTPRANDIAL PERIOD; SAFFLOWER OIL; TRIGLYCERIDES;

EID: 3042740696     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/80.1.45     Document Type: Article

References (55)

1. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arteriosclerosis 1997;17:715-22.
2. Karpe F, Hellénius M-L, Hamsten A. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease. Metabolism 1999;48:301-7.
3. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97.
4. Sharrett AR, Chambless LE, Heiss G, Patton CC, Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 1995;15:2122-9.
5. van Bockxmeer FM, Liu Q, Mamotte C, Burke V, Tayor R. Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids. Atherosclerosis 2001;157:123-9.
6. Miles JM, Park Y, Harris WS. Lipoprotein lipase and triglyceride-rich lipoprotein metabolism. Nutr Clin Prac 2001;16:273-9.
7. Eckel RH. Lipoprotein lipase - a multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989;320:1060-9.
8. Glaser DS, Yost TJ, Eckel RH. Preheparin lipoprotein lipase activities: relationship to plasma lipoproteins and postheparin lipolytic activities. J Lipid Res 1992;33:209-14.
9. Harris WS, Lu G, Rambjor GS, et al. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am J Clin Nutr 1997;66:254-60.
10. Vilella E, Joven J, Fernandez M, et al. Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. J Lipid Res 1993;34:1555-64.
11. Watson TDG, Tan CE, McConnell M, Clegg SK, Squires LF, Packard CJ. Measurement and physiological significance of lipoprotein and hepatic lipase activities in preheparin plasma. Clin Chem 1995;41:405-12.
12. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003;44:455-63.
13. Nozaki S, Garg A, Vega GL, Grundy SM. Postheparin lipolytic activity and plasma lipoprotein response to ω-3 polyunsaturated fatty acids in patients with primary hypertriglyceridemia. Am J Clin Nutr 1991;53:638-42.
14. Harris WS, Connor WE, Alam N, Illingworth DR. Reduction of postprandial triglyceridemia in humans by dietary omega-3 fatty acids. J Lipid Res 1988;29:1451-60.
15. Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL. Dietary polyunsaturated fats of the w-6 and w-3 series reduce postprandial lipoprotein levels. J Clin Invest 1988;82:1884-93.
16. Desager JP, Dricot J, Harvengt C. Hypotriglyceridemic action of omega-3 fatty acids in healthy subjects does not occur by enhanced lipoprotein lipase and hepatic lipase activities. Res Commun Chem Pathol Pharmacol 1989;65:269-72.
17. Jensen DR, Schlaepfer IR, Morin CL, et al. Prevention of diet-induced obesity in transgenic mice overexpressing skeletal muscle lipoprotein lipase. Am J Physiol 1997;273:R683-9.
18. van Bennekum AM, Kako Y, Weinstock PH, et al. Lipoprotein lipase expression level influences tissue clearance of chylomicron retinyl ester. J Lipid Res 1999;40:565-74.
19. Iverius P-H, Brunzell JD. Human adipose tissue lipoprotein lipase: changes with feeding and relation to postheparin plasma enzyme. Am J Physiol 1985;249:E107-14.
20. Stalenhoef AF, Malloy MJ, Kane JP, Havel RJ. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia. J Clin Invest 1986;78:722-8.
21. Karpe F, Olivecrona T, Hamsten A, Hultin M. Chylomicron/chylomicron remnant turnover in humans: evidence for margination of chylomicrons and poor conversion of larger to smaller chylomicron remnants. J Lipid Res 1997;38:949-61.
22. Hultin M, Savonen R, Olivecrona T. Chylomicron metabolism in rats: lipolysis, recirculation of triglyceride-derived fatty acids in plasma FFA, and fate of core lipids as analyzed by compartmental modelling. J Lipid Res 1996;37:1022-36.
23. Harris KL, Harris PA. Kinetics of chylomicron triglyceride removal from plasma in rats: effect of dose on the volume of distribution. Biochim Biophys Acta 1973;326:12-6.
24. Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein lipase and hepatic lipase. Curr Opin Lipidol 1990;1:222-30.
25. Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest 1992;90:2013-21.
26. Harris WS, Connor WE. The effects of salmon oil upon plasma lipids, lipoproteins and triglyceride clearance. Trans Assoc Am Physicians 1980;43:148-55.
27. Harris WS, Rothrock DW, Fanning A, et al. Fish oils in hypertriglyceridemia: a dose-response study. Am J Clin Nutr 1990;51:399-406.
28. Harris WS, Windsor SL. N-3 fatty acid supplements reduce chylomicron levels in healthy volunteers. J Appl Nutr 1991;43:5-15.
29. Harris WS, Muzio F. Fish oil reduces postprandial triglyceride concentrations without accelerating lipid emulsion removal rates. Am J Clin Nutr 1993;58:68-74.
30. Harris WS, Windsor SL, Caspermeyer JJ. Modification of lipid-related atherosclerosis risk factors by ω3 fatty acid ethyl esters in hypertriglyceridemic patients. J Nutr Biochem 1993;4:706-12.
31. Khan S, Minihane AM, Talmud PJ, et al. Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res 2002;43:979-85.
32. Sztern MI, Harris WS. Short-term effects of fish oil on human plasma lipid levels. J Nutr Biochem 1991;2:255-9.
33. Park Y, Damron BD, Miles JM, Harris WS. Measurement of human chylomicron triglyceride clearance with a labeled commercial lipid emulsion. Lipids 2001;36:115-20.
34. Blache D, Bouthillier D, Davingnon J. Simple, reproducible procedure for selective measurement of lipoprotein lipase and hepatic lipase. Clin Chem 1983;29:154-8.
35. Baginsky ML, Brown WV. A new method for the measurement of lipoprotein lipase in postheparin plasma using sodium dodecyl sulfate for the inactivation of hepatic triglyceride lipase. J Lipid Res 1979;20:548-56.
36. Grundy SM, Mok HYI. Chylomicron clearance in normal and hyperlipidemic man. Metabolism 1976;25:1225-39.
37. Harris WS. n-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65(suppl):1645S-54S.
38. Park Y, Grellner WJ, Harris WS, Miles JM. A new method for the study of chylomicron kinetics in vivo. Am J Physiol 2000;279:E1258-63.
39. Karpe F, Olivecrona T, Walldius G, Hamsten A. Lipoprotein lipase in plasma after an oral fat load: relation to free fatty acids. J Lipid Res 1992;33:975-84.
40. Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 1995;15:1086-93.
41. Eckel RH, Goldberg IJ, Steiner L, Yost TJ, Paterniti JR Jr. Plasma lipolytic activity: relationship to postheparin lipolytic activity and evidence for metabolic regulation. Diabetes 1988;37:610-5.
42. Cheng Q, Blackett PR, Wang CS, Fesmire JD, Corder CN. Use of plasma lipoprotein lipase activity without heparin injection for detection of homozygous and heterozygous lipoprotein lipase deficiency. Ann N Y Acad Sci 1991;623:410-2.
43. Hitsumoto T, Ohsawa H, Uchi T, et al. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis 2000;153:391-6.
44. Hitsumoto T, Yoshinaga K, Aoyagi K, et al. Association between preheparin serum lipoprotein lipase mass and acute myocardial infarction in Japanese men. J Atheroscler Thromb 2002;9:163-9.
45. Henderson HE, Kastelein JJ, Zwinderman AH, et al. Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. J Lipid Res 1999;40:735-43.
46. Dugi KA, Schmidt N, Brandauer K, Ramacher D, Fiehn W, Kreuzer J. Activity and concentration of lipoprotein lipase in post-heparin plasma and the extent of coronary artery disease. Atherosclerosis 2002;163:127-34.
47. Haglund O, Luostarinen R, Wallin R, Wibell L, Saldeen T. The effects of fish oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E. J Nutr 1991;121:165-9.
48. Baginsky ML, Brown WV. Differential characteristics of purified hepatic triglyceride lipase and lipoprotein lipase from human postheparin plasma. J Lipid Res 1977;18:423-37.
49. Harris WS, Hustvedt BE, Hagen E, Green MH, Lu G, Drevon CA. N-3 fatly acids and chylomicron metabolism in the rat. J Lipid Res 1997;38:503-15.
50. Zampelas A, Murphy M, Morgan M, Williams CM. Postprandial lipoprotein lipase, insulin and gastric inhibitory polypeptide responses to test meals of different fatty acid composition: comparison of saturated, n-6 and n-3 polyunsaturated fatty acids. Eur J Clin Nutr 1994;48:849-58.
51. Levy E, Thibault L, Turgeon J, et al. Beneficial effects of fish-oil supplements on lipids, lipoproteins, and lipoprotein lipase in patients with glycogen storage disease type I. Am J Clin Nutr 1993;57:922-9.
52. Luo J, Rizkalla SW, Vidal H, et al. Moderate intake of n-3 fatty acids for two months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. Diabetes Care 1998;21:717-24.
53. Leibowitz MD, Fievet C, Hennuyer N, et al. Activation of PPAR-delta alters lipid metabolism in db/db mice. FEBS Lett 2000;473:333-6.
54. Thoennes SR, Tate PL, Price TM, Kilgore MW. Differential transcriptional activation of peroxisome proliferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells. Mol Cell Endocrinol 2000;160:67-73.
55. Chambrier C, Bastard JP, Rieusset J, et al. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes Res 2002;10:518-25.